ArticleIndian journal of ophthalmology2026
Efficiency of anti-vascular endothelial growth factor drug switch in patients who did not respond to a series of bevacizumab injections.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the effectiveness of switching anti-vascular endothelial growth factor (VEGF) agents in eyes with retinal pathologies that poorly respond to intravitreal bevacizumab injections.
methodsWe compared central macular thickness (CMT) and VA between eyes with suboptimal responses to at least three bevacizumab injections that either continued with bevacizumab or switched to aflibercept or ranibizumab. Eyes were categorized into group D (DME), group N (neovascular age-related macular degeneration [nAMD]), and group A - all eyes (D and N plus eyes with retinal vein occlusion (RVO) or pseudophakic central macular edema [PCME]). Each group was further divided into those continuing bevacizumab (D1, N1, A1) or switching to aflibercept or ranibizumab (D2, N2, A2).
resultsA total of 21 eyes were included in group D (8 in D1 and 13 in D2), 28 in group N (14 in N1 and 14 in N2), and 59 eyes in group A (25 in A1 and 34 in A2). In all eyes with treatment shift, CMT decreased: 38.5 (SD: 46.2), 92.6 (SD: 106.8), and 82.1 (SD: 115.6) microns in D2, N2, and A2, respectively. CMT difference was statistically significant between N1 versus N2 and between A1 versus A2 ( P = 0.025 and 0.004, respectively). No significant difference in VA was observed.
conclusionSwitching anti-VEGF agents appears anatomically beneficial in nonresponding eyes. Notably, the inclusion of a control group continuing bevacizumab despite poor response allows for a more reliable evaluation of treatment efficacy, addressing a key limitation of prior studies and contributing to the evidence-based rationale for agent switching.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.